Ocera Therapeutics, Inc. To Present At Stifel 2014 Healthcare Conference
PALO ALTO, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be presenting at the Stifel 2014 Healthcare Conference being held at the Palace Hotel in New York, NY. Ocera's presentation is scheduled for Wednesday, November 19, 2014 at 3:00 PM ET in the Homes II conference room.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 30 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
CONTACT: Susan Sharpe Ocera Therapeutics, Inc. contact@ocerainc.com 919-328-1109 
Help employers find you! Check out all the jobs and post your resume.